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a  b  s  t  r  a  c  t
Prior  studies  demonstrate  that  a  proteinase  fraction  from  Vasconcellea  cundinamarcensis  V.M.  Badillo,  Car-
icaceae,  exhibits  wound  healing  activity in  gastric  and  cutaneous  models  and  antitumoral/antimetastatic
effects.  Here,  we  present  the  toxicity,  pharmacokinetics  and  biodistribution  data  for  this  proteinase  frac-
tion  following  a single  dose into  Swiss  mice  by i.v., s.c. or p.o.  routes.  The  i.v.  and s.c.  toxicity  assays
demonstrate  that proteinase  fraction  at ≤20  mg/kg  is non-lethal  after  single  injection,  while  parental
administration  (p.o.)  of  ≤300  mg/kg  does  not  cause  death.  Based  on  p.o.  acute  toxicity  dose  using  Organisa-
tion for  Economic  Cooperation  and  Development  protocols,  proteinase  fraction  ranks  as  Class  IV “harmful”
substance.  Proteinase  fraction  shows  high  uptake  determined  as  Kp  (distribution  tissue/blood)  in organs
linked  to metabolism  and  excretion.  Also,  high  bioavailability  (≈100%)  was  observed  by  s.c. adminis-
tration.  The  blood  contents  following  i.v.  dose  ﬁts  into  a  pharmacokinetic  bi-compartmental  model,
consisting  of  high  removal  constants  – k 0.22  h−1 and  k 2.32  h−1and  a half-life  –  t = 3.13  h. The  Amesel d ½
test  of  proteinase  fraction  (0.01–1%)  demonstrates  absence  of mutagenic  activity.  Likewise,  genotoxic
evaluation  of proteinase  fraction  (5 or 10 mg/kg,  i.p.)  shows  no inﬂuence  in micronuclei  frequency.  In
conclusion,  the  acute  doses  for proteinase  fraction  lack  mutagenic  and  genotoxic  activity,  clearing  the
way for  clinical  assays.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
The study of plant cysteine proteinases attracts interest because
f their multiple alleged activities. The pharmacological action
escribed for these proteins include anthelmintic action against
ematode infection (Gomes et al., 2011), anti-inﬂammatory activ-
ty (Gaspani et al., 2002; Brien et al., 2004) wound debridant (Ford
t al., 2002; Ayello and Cuddigan, 2004; Melano et al., 2004) and to
ntagonize animal morbidity due to septic shock (Lima-Filho et al.,
010). The antitumoral/antimetastatic activity is perhaps one of
he most attractive properties of plant cysteine proteinases, as this
ffect was demonstrated in enzymes from different sources (Beuth,
008; Wald, 2008).
Cysteine proteinases from Vasconcellea cundinamarcensis V.M.
adillo latex have been characterized biochemically (Teixeira et al.,
008) and pharmacologically by our research group. The species
s member of the Caricaceae family common to many areas in
∗ Corresponding author.
E-mail: cesbufmg@icb.ufmg.br (C.E. Salas).
http://dx.doi.org/10.1016/j.bjp.2015.09.008
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier EditoraSouth America. Until now, studies using P1G10, a proteinase frac-
tion obtained by gel ﬁltration on Sephadex G-10, shows interesting
pharmacological activities, such as; wound healing of dermabra-
sions (Lemos et al., 2011), burns (Gomes et al., 2010), gastric
ulcer protective and healing effects by p.o.  route (Mello et al.,
2006, 2008; Araujo e Silva et al., 2015). Besides, mitogenic, angio-
genic and anti-inﬂammatory effects are evident along with the
healing effect. Subcutaneous administration of P1G10 exhibits
antitumor/antimetastatic activity. Apoptosis, inhibition of angio-
genesis and a loss of cell adhesion to extracellular components
are associated to the antitumoral effect (Dittz et al., 2010, 2015).
In addition, s.c. proteolitically active P1G10 acts as antithrombotic
(Bilheiro et al., 2013) and this effect is accompanied by a decline
in platelet activation, increase in prothrombin (PT), thrombin (TT)
and activated partial thromboplastin times (APTT), along with ﬁb-
rinogenolytic and ﬁbrinolytic action.Previous in vivo studies (Lemos et al., 2011) demonstrate that
P1G10 at concentrations 10-fold higher than the effective dose
(0.1%, w/w in Polawax®) does not induce apparent changes on
intact skin. Also, continuous topical application of P1G10 0.1%
 Ltda. All rights reserved.
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uring 6-month did not induce skin damage as demonstrated
y microscopic examination. Also, chronically (6-month) treated
pecimens showed no changes in weight or histology of organs. The
bsence of systemic effect was anticipated considering the small
mount of active principle in Polawax® that permeates intact or
cariﬁed skin (<0.3% and 26% relative to the total amount applied,
espectively) (Lemos et al., 2011).
In this study, we synthesize 99mTc-P1G10 to evaluate the phar-
acokinetics parameters following a single injection, and study the
oxicological and mutagenic effects aiming studies at prospective
herapeutic use of the formulated product.
aterial and methods
aterials
Unripe fruits of Vasconcellea cundinamarcensis V.M. Badillo, Car-
caceae, 2–4 year-old, were the source of latex used in this study.
 voucher specimen of the plant was deposited at the herbarium
f the Universidad de La Serena, Chile, with #15063. Benzoyl-
,l-arginine-p-nitroanilide (BAPNA) was from Sigma Co. Sephadex
-10 and G-15 were from GE Healthcare, 99mTc was produced in a
9Mo/99mTc generator and provided by IPEN (São Paulo, Brazil) and
ach reagent used was analytical grade.
nimals
Swiss mice (male and female), approximately 8-weeks old,
ere obtained from CEBIO-ICB, UFMG animal facility and housed
n polycarbonate cages with sawdust bedding and maintained in
nvironmentally controlled rooms (22 ± 2 ◦C and 50 ± 10% rela-
ive humidity) with a 12-h light-dark cycle (light from 7 a.m. to
 p.m.). Food and water were available ad libitum. The project was
pproved by the Ethics Committee on Animal Experimentation
CETEA) from UFMG (Process no. 236/2008 and 91/2009).
ethods
solation and characterization of P1G10 fraction
Latex was collected by making three longitudinal incisions onto
he surface of unripe fruits with the aid of a sharp steel blade.
ollowing collection into a plastic dark container, it was stored
t −20 ◦C until lyophilized. Dried latex was dissolved and incu-
ated at room temperature in buffer containing 25 mM l-cysteine,
 mM DTT, 10 mM EDTA pH 5.0 in 1 M sodium acetate solution.
he suspension was centrifuged at 4000 × g 10 min  at room tem-
erature and the ﬁltered supernatant (Whatman #1) applied onto
 Sephadex G-10 (25 mm × 400 mm)  previously equilibrated with
 M sodium acetate pH 5.0. The ﬁrst A280 nm protein absorb-
ng fraction containing the bulk proteolytic activity, designated as
1G10 was concentrated by ultraﬁltration (10,000 Da pore size) and
ashed three times with an equivalent volume of distilled water,
yophilized and stored at −20 ◦C until used. The recovered yellow-
sh powder was analyzed for its proteolytic and amidase activities,
lectrophoretic mobility by SDS-PAGE and the HPLC retention time,
s described by Mello et al. (2008).
rotein radiolabeling
P1G10 (1 mg)  was labeled with 37 MBq  Na99mTcO4, 3.7 mM
nCl2 and 2.6 mM  NaBH4 in a total volume of 200 l and incubated
or 20 min  at room temperature as described elsewhere by Nunan
t al. (2002). The labeling efﬁciency was assessed by the method
dapted from the United States Pharmacopeia (USP 24, 2000). An
liquot of the reaction mix  (2 l) was initially cromatographed on
scending Silica gel 60 chromatography (TLC Merck) followed by
hatman #1 descending paper chromatography to monitor label-
ng efﬁcacy. During the ﬁrst TLC step 5 l of the reaction mixarmacognosia 26 (2016) 94–101 95
were spotted onto a silica plate and after sample drying the chro-
matogram was developed with acetone. The strip was scrapped off
and 1 cm2 fractions placed in vials and counted in an Automatic
Scintilator (ANSR-Abbot, USA). Under this condition, the reduced
technetium plus the radiolabeled protein remain at the applica-
tion site while oxidized Tc (99mTcO4−) migrated with the front of
the solvent allowing assessment of the percentage of 99mTcO4. For
descending chromatography 5 l of reaction mix  were applied onto
a Whatman paper strip (15 cm × 36 cm)  previously saturated with
1% BSA solution. Saline solution (0.9%) was used to develop the
chromatogram. Again, the strip of paper was  cut into fractions and
each fraction placed into vials and the radioactivity measured in an
Automatic Scintilator, as before. Under these conditions 99mTcO4−
and 99mTc-P1G10 migrate with the solvent front, while 99mTcO2
remain at the origin. The percent 99mTcO2 is determined by the
distribution of radioactivity on the paper strip. The labeling yield
was calculated as follows:
Labeling yield (%)
= cpm
99mTc-P1G10
Total cpm(99mTc − P1G10 + 99mTcO4 + 99mTcO2)
The proportion of labeled protein relative to free 99mTcO2 was
established after running parallel Sephadex G-15 (4.0 cm × 1.5 cm)
chromatographies of the labeled protein (P1G10) and a control con-
taining only the tracer equilibrated with 0.9% (w/v) NaCl (Nunan
et al., 2002). Radioactive fractions of P1G10 were subsequently
pooled and used in experiments within the next 24 h following
protein labeling.
Pharmacokinetics and tissue distribution of 99mTc-P1G10
Swiss male mice (25–30 g, 8–10 weeks, n = 48) received 1 mg/kg
99mTc-P1G10 (0.1 ml/30 g body weight) intravenously (i.v.), sub-
cutaneously (s.c.) or orally (p.o.). The animals were sacriﬁced
by exsanguination at different intervals (0.25, 0.5, 1, 2, 4, 8, 12
and 24 h), under anesthesia with a xilazine (9 mg/kg) ketamine
(60 mg/kg) mixture. Blood and urine were collected and spleen,
bladder, brain, heart, stomach, liver, small- and large intestine,
skin, lung, kidney, adipose tissue and thyroid were removed and
weighed. The radioactivity in organs and blood was  measured with
an automatic scintillation counter (ANSR-Abbot, USA). The results
were expressed as percentage of the injected dose per g of tis-
sue or ml of blood. The correction for the radioisotope decay was
done by simultaneous counting at a speciﬁc interval of the residual
tracer equivalent to the initially injected dose. The resulting values
were plotted using Graph Pad Prism 5 software for determination of
radioactivity versus time and their respective areas under the curve
(AUC) and the rate constants kel and kd by a nonlinear regression
model. Using the elimination constant – kel (slow rate slope), we
calculated the half-life time (t½) = 0.693/kel. The values for bioavail-
ability (F) during p.o. and s.c.  treatments were calculated by the
equation:
F = [AUC (s.c. or p.o.) × Dose (i.v.) × 100]
[AUC (i.v.) × Dose (s.c. or p.o.)]
The partition coefﬁcient of tissue versus blood (Kp) was deter-
mined by the ratio; AUCorgan/AUCblood as before by Gibaldi and
Perrier (1982).
Acute oral toxicity test
Swiss female mice were allowed to adapt for 7 days before treat-
ment. After this period, P1G10 (5, 10, 20 or 300 mg/kg) or the vehicle
(0.9% NaCl–saline) were administrated intravenously (i.v.), subcu-
taneously (s.c.) or by gavage (p.o.) at a single dose. Mice survival
and clinical signs were scored (abdominal contraction, tremors,
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air coat, convulsions, paralysis, muscle tone, behavior – restless-
ess, apathy and isolation, or others), following OECD 420 guideline
2001). After 14-days observation, mice were sacriﬁced and the
rgans macroscopically examined and weighed. All clinical signs
ere recorded and classiﬁed according to the intensity of the effects
s follows: absent (−), present or slightly (+), moderately (++), and
trongly increased (+++).
utagenicity testP1G10 was assayed for its mutagenic activity using the
almonella typhimurium (strains TA97, TA98, TA100 and TA102)
rocedure with and without S9 activation (Maron and Ames,
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ig. 1. Chromatographic puriﬁcation and characterization of radiolabeled 99mTc P1G10. (
-15  column. Two hundred microliters of P1G10 (5 g/l) or 99mTc-P1G10 (5 g/l  – 1
ractions (0.7 ml)  were collected at ﬂow rate 0.7 ml/min. The protein proﬁle was determ
DS-PAGE electrophoresis of P1G10 and 99mTc-P1G10. Heat-denatured protein samples 
everse-phase chromatography of 99mTc-P1G10. The C4 column (Vydac) was equilibrated 
ollowed by elution with a non-linear acetonitrile – 0.1% TFA gradient at a ﬂow rate of 
cetonitrile for 10 min).armacognosia 26 (2016) 94–101
1983). Bacterial stocks (10 l) were initially incubated in nutrient
medium for 12–18 h at 37 ◦C with shaking followed by inocu-
lation in agar/histidine/biotin plates and incubated at 37 ◦C for
48 h, as described by Mortelmans and Zeiger (2000). The bacte-
rial cultures (100 l) grown from isolated colonies were added
to 500 l of S9 or phosphate buffer (-S9) and 200 l of positive
control, negative control (deionized water) or P1G10 (0.1, 1 or
10 mg/ml) and 500 l of agar containing biotin–histidine (0.5 mM)
and incubated at 37 ◦C for 48 h. Sodium azide (5 g/plate, TA100), 4-
nitro-o-phenylenediamine (2.5 g/plate, TA98), 9-aminoacridine
(50 g/plate TA97), and mitomycin C (5 g/plate, TA102) were
used as positive controls without enzymatic induction while 2-
aminoanthracene (5 g/plate) was  used with each strain, in the
D
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Table 1
Partition coefﬁcient of 99mTc-P1G10 in mice organs.
Organ Administration routes
i.v. s.c. p.o.
AUC Kp AUC Kp AUC Kp
Blood 10.9 1.0 12.1 1.0 0.9 1.0
Liver 45.2 4.1 19.2 1.6 2.1 2.3
Spleen 12.7 1.2 6.5 0.5 0.7 0.8
Stomach 7.9 0.7 5.3 0.4 292.2 323.9
Small intestine 12.3 1.1 11.9 1.0 55.0 61.0
Large intestine 57.2 5.2 30.9 2.6 400.6 444.1
Kidney 504.9 46.3 490.9 40.7 5.6 6.2
Bladder/urine 1192.0 109.3 1263.0 104.6 29.4 32.6
Thyroid 5.7 0.5 8.3 0.7 1.5 1.6
Fat 3.5 0.3 3.1 0.3 0.3 0.4
Brain 0.6 0.1 1 0.1 0.1 0.1
Heart 6.9 0.6 6.7 0.6 0.6 0.7
Lung 10.7 1.0 8.7 0.7 0.7 0.8
Skin 7.8 0.7 7.5 0.6 1.6 1.8
(109.3 and 104.6) and lower in metabolic organs; liver (4.1 and 1.6)
large intestine (5.2 and 2.6), respectively. In addition, Kps for stom-
ach (323.9) and small intestine (444.1) became comparatively large
during p.o. injection. On the other hand, in adipose tissue, brain
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resence of S9 microsomal fraction. The samples were assayed in
riplicate and the results expressed as the number of colony rever-
ant colonies per plate (Maron and Ames, 1983; Mortelmans and
eiger, 2000). Statistical analysis was performed by ANOVA fol-
owed by Bonferroni post-test (p < 0.05). Mutagenicity ratio (MR)
as expressed as the ratio between the number of revertant
olonies for the sample and the negative control.
icronucleus test
Male Swiss mice were treated with vehicle (castor oil) –
egative control, cyclophosphamide (50 mg/kg) – positive control
r P1G10 (5 mg/kg or 10 mg/kg), i.p.,  in a single dose (n = 5). After
6 h interval, the animals were sacriﬁced by cervical dislocation and
he bone marrow immediately ﬂushed out from femora and tibia
sing 3 ml  of fetal bovine serum and centrifuged at 1200 × g, 1 min.
he pellet was suspended in 0.5 ml  fetal bovine serum and smears
ere prepared on microscope slides, air dried and stained with
ay  Grunwald. The frequency of polychromatic erythrocyte (PCE)
icronucleated (at least 1 micronucleus) was determined after
coring 2000 PCE by slide (3/animal). Statistical analyzes were per-
ormed by ANOVA test followed by Bonferroni post-test (p < 0.05).
esults
P1G10 represents the bulk of proteolytic activity recovered
rom latex after Sephadex-G10 ﬁltration as described earlier by
ello et al. (2008). To verify the uniformity of P1G10, sev-
ral P1G10 batches from different latex stocks were analyzed
onﬁrming identical electrophoretic proﬁles on 12% SDS-PAGE
Supplementary Fig. 1A). The two higher size bands in Sup-
lementary Fig. 1A, lines 1–5 (58 kDa and 90 kDa) represent
rotein aggregates, formed during lyophilization (observe that total
atex sample lacks these bands, lanes 6–8). We  further conﬁrm
he presence of four major protein peaks following C4-reverse
hase HPLC chromatography (Supplementary Fig. 1B). The result-
ng protein concentration and amidase activity of P1G10 were
.39 ± 0.39 mg/ml  and 13.5 ± 0.5 nM/g × min, respectively; this
raction was further used in toxicological and pharmacokinetics
xperiments described below.
iodistribution and pharmacokinetics
Under this labeling condition 74.5 ± 6.4% (n = 6) yield of radio-
abeled protein was recovered when reacting 1 mg  P1G10 with
7 MBq  Na99mTcO4, 3.7 mM SnCl2 and 2.6 nM NaBH4, plus a small
mount of TcO4− (0.1–1.0%) and 20–30% of TcO2, as conﬁrmed by
escending and ascending chromatographies (not shown). Fig. 1A
llustrates the elution proﬁle of the radiolabeled protein, following
ephadex G-15 chromatography. It shows a coincident radioac-
ive and protein proﬁle; the pooled fractions (3–5) representing
0–50% of the applied radioactivity and 92% of the loaded protein, as
ssessed by absorption at UV280 nm.  Two control cromatographies
re included in Fig. 1B and C. The ﬁrst one shows the protein proﬁle
A280 nm)  corresponding to P1G10 incubated without the radioac-
ive, and the second one, the elution proﬁle of TcO2 after incubation
ith other ingredients but without the protein. Both radioactive
eaks elute in similar fractions (compare Fig. 1A and 1C), indicat-
ng that the radioactivity in Fig. 1A is mostly due to 99mTc-P1G10.
he assumption is also based on the amount of radioactivity recov-
red in fraction 5 (Fig. 1C) that represents less than 3% of the
otal amount loaded in the column (37 mBq). It suggests that the
nreacted radioactivity is held in the column after extensive wash-
ng, while the radioactivity recovered in the protein peak (Fig. 1A)
pproaches 50% of the amount applied.AUC, area under the curve; Kp, partition coefﬁcient; Administration routes: i.v.,
intravenous; s.c., subcutaneous; p.o., oral. Dose: 1 mg/kg 99mTc-P1G10. Radioactive
dose = 3 mBq.
The electrophoretic and HPLC proﬁles of 99mTc-P1G10 were
evaluated to verify the existence of possible changes in mobility or
retention due to radiolabeling. The protein proﬁle depicting species
with Mw ≈ 25 kDa is similar in both, the P1G10 and the 99mTc-
P1G10 fractions (Fig. 1D). Also, the HPLC proﬁle and the retention
time of 99mTc-P1G10 (Fig. 1E) using a C4 hydrophobic chromatog-
raphy was similar to the P1G10 (Supplementary Fig. 1B). Besides,
the overlap of radioactive and absorbance peaks indicate that the
bulk of the protein is radiolabeled (Fig. 1E). The stability of 99mTc-
P1G10 was  determined by incubation of the fraction at 37 ◦C during
various intervals (0–24 h) of the radiolabeled protein with plasma
withdrawn from Swiss mice. It was observed that the percentage of
99mTcO4− plus TcO2 present in the mix  remained stable totalizing
10% of total radioactivity after the incubation period, arguing for
the stability of 99mTc-P1G10 complex (Supplementary Table 1). In
short, the experimental evidence suggests that radiolabeled P1G10
remains essentially similar to the unlabeled protein and represents
the major species available following protein radiolabeling.
The 99mTc-P1G10 distribution expressed as partition coefﬁcient
(Kp – AUC organ/AUC blood) is shown in Table 1 and the uptake
kinetics of 99mTc-P1G10 in different organs is presented in supple-
mentary Fig. 2. Overall, i.v.  or s.c. administration resulted in high
Kps in organs linked to excretion; kidney (46.3 and 40.7), bladderFig. 2. Blood radioactive clearance of 99mTc-P1G10 injected in Swiss mice. Blood
clearance of 99mTc-P1G10 (experimental, ) and the nonlinear theoretical regression
plot (. . ..), after i.v. administration. The ordinate is expressed as radioactivity (log
scale) relative to the initial injected radioactivity (cpm) per ml of blood (R2 = 0.9998).
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Table  2
Pharmacokinetic parameters of 99mTc-P1G10 in Swiss mice.
Pharmacokinetic parameters
kd (h−1) 2.32 ± 1.03
kel (h−1) 0.22 ± 0.20
t½ distribution (h) 0.29 ± 0.67
t½ elimination (h) 3.13 ± 3.42
AUC (% dose/ml × h) 10.9
Oral bioavailability (%) 8.3
Subcutaneous bioavailability (%) 111
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Table 3
Systemic toxicity following a single dose of P1G10 in Swiss mice.
Route Dose
(mg/kg)
T/D T/P Clinical signs
i.v.
Control 5/0 (−) (−)
5 5/0 5/2 Phlebitis (+)
Remission 7–12 days
10 5/0 5/3 Phlebitis (++)
Remission 7–12 days
20 5/0 5/5 Phlebitis (+++)
Remission 7–14 days
s.c.
Control 5/0 (−) (−)
5 5/0 (−) (−)
10 5/0 5/2 Cutaneous lesion (++)
Remission in 9 days
20  5/0 5/5 Cutaneous lesion (+++)
Remission 9–14 days
p.o.
Control 5/0 (−) (−)
5 5/0 (−) (−)
10 5/0 (−) (−)
300 5/0 (−) (−)
A single dose of P1G10 was given by i.v.,  s.c.  or p.o. route. T/D = number of treated
animals/number of deaths, T/P = number of treated animals/number of positive
symptoms, n = 5. The examination period for clinical signs after single administra-
tion  was 15, 30, 60 min and every hour during 12 h and daily during 14 days. The
T
M
S
1
9
mhe pharmacokinetic data for 99mTc-P1G10s was  determined after a single dose
f  1 mg/kg 99mTc-P1G10. Radioactive dose = 3 MBq. kd, distribution constant; kel,
limination constant; t½, half-life; AUC, area under the curve.
eart, lung, thyroid and skin Kps became lower or remain close to
lood levels, regardless of the administration route.
The pharmacokinetics parameters following i.v. administration
f 99mTc-P1G10 obtained by plotting the log of percent radioac-
ivity in blood versus time during a 24 h interval, is shown in
ig. 2. The proﬁle of radioactive decay was assimilated into a
wo-compartment open model composed by an initial fast phase,
epresenting mainly the distribution phase (0–3 h) and the sub-
equent slow phase corresponding to the disposal phase (5–12 h).
he estimated half-life of the distribution phase was  0.3 h and for
he disposition phase was 3 h. A summary of the pharmacokinetics
arameters is presented in Table 2.
We also compared the bioavailability of 99mTc-P1G10 following
hree strategies for administration. Clearly, i.v. and s.c.  provide the
argest availability attaining 100% in both cases, on the other hand
ral administration resulted in limited bioavailability attaining less
han 10% (Table 2).
cute toxicity
In Table 3, P1G10 toxicity was shown as number of obits or the
umber of animals bearing clinical signs, a principal toxic event
escribed by OECD 420 (2001). These results show absence of tox-
cological symptoms, both in controls and P1G10 treated animals
egardless the administration route, after 14-days of treatment. The
bsence of toxicity was conﬁrmed by histopathology of different
rgans (heart, liver, spleen, kidney, stomach, lung and large/small
ntestine) (data not shown). Although toxic effects at the local of
njection were observed in the groups treated by i.v. and s.c.  routes,
emission of the signs occurred until the 14th day. Using the largest
able 4
utagenic activity of P1G10 using the Salmonella typhimurium – Ames test.
Treatment (mg/plate) Rev
TA98 TA100 
−S9 +S9 −S9 +S9 
Negative control
(H2O)
21.7 ± 4.1 25.0 ± 5.4 165.3 ± 27.1 155.3 ±
P1G10
0.1  mg
(MR)
31.3 ± 1.8
(1.4)
24.3 ± 3.4
(0.9)
81.3 ± 17.4
(0.5)
66.7 ± 2
(0.4)
1.0  mg
(MR)
19.3 ± 3.4
(0.9)
23.3 ± 2.4
(0.9)
88.0 ± 17.3
(1.0)
105.3 ±
(1.6)
10  mg
(MR)
15.3 ± 2.4
(0.7)
27.3 ± 0.3
(1.1)
124.0 ± 25.7
(0.7)
117.3 ±
(0.7)
Positive control
(MR)
132.9 ± 32.9*
(6.2)
118.6 ± 22.0
(4.7)
1211.9 ± 112.6*
(7.3)
1561.3
(10.0)
almonella typhimurium strains: TA 97, TA 98, TA 100 and TA 102; +S9 or −S9, plus or m
0  mg/plate); negative control: 100 l/plate (H2O); positive control: for TA 98, 4-nitro-o
-aminoacridine (50 mg/plate); TA 102, mitomycin C (0.5 g/plate); with S9 – TA 97, 98, 
utants relative to negative control.
* p < 0.05 ANOVA, Bonferroni post-test.control vehicle was 0.9% NaCl. Code for observed symptoms: (−), absent; (+), present
or  slightly increased; (++), moderately increased; (+++), strongly increased.
i.v. dose (20 mg/kg) every animal exhibited severe symptoms of
phlebitis. Forty and 60% of animals that received 5 and 10 mg/kg,
respectively, showed slight or moderate signs of phlebitis. During
s.c. administration, all animals showed severe cutaneous lesions at
the application site with 20 mg/kg, whereas 40% of animals that
received 10 mg/kg showed light to moderate sign of lesions.
The mutagenic activity of P1G10 measured by Ames test is pre-
sented in Table 4. The different concentrations of P1G10 (0.1, 1.0
and 10.0 mg/plate) did not induce reversion above background
with the four strains analyzed, both, in the absence or presence
of the microsomal activation extract (S9). A reference positive
control showing signiﬁcantly higher reversion was  included with
these experiments (p < 0.05, ANOVA, Bonferroni post-test). Using
the micronuclei test to conﬁrm the lack of mutagenic activity,
we show in Fig. 3 that P1G10 at 5 (26.48 ± 8.94) and 10 mg/kg
(24.56 ± 16.73) did not induce micronucleation above the control
(castor oil) 40.82 ± 16.58) and was  signiﬁcantly lower than the
ertant colonies (mean ± SD)
TA97 TA102
−S9 +S9 −S9 +S9
 25.5 171.7 ± 19.4 138.3 ± 11.4 126.7 ± 15.8 133.3 ± 18.9
.9 134.7 ± 27.5
(0.8)
100.3 ± 3.2
(0.72)
77.0 ± 1.2
(0.6)
128.0 ± 24.7
(1.0)
 10.4 128.7 ± 52.9
(0.7)
64.3 ± 4.0
(0.5)
107.0 ± 1.2
(0.8)
155.0 ± 3.9
(1.2)
 12.6 94.7 ± 1.1
(0.5)
29.3 ± 2.9
(0.2)
69.7 ± 3.5
(0.5)
166.7± 11.1
(1.2)
 ± 121.1* 861.33 ± 174.74*
(5.0)
278.6 ± 106.9*
(2.1)
1976.6 ± 159.2*
(15.6)
1799.6 ± 154.1*
(13.5)
inus metabolic activator, respectively. Triplicate assays contained P1G10 (0.1, 1,
-phenylenediamine (2.5 mg/plate); TA 100, sodium azide (1.25 mg/plate); TA 97,
100 and 102, 2-aminoanthracene (5 mg/plate). MR = mutagenesis rate: number of
F.O. Lemos et al. / Revista Brasileira de F
NC PC  5 mg/kg 10 mg/kg
0
50
100
150
200
250
***
P1G10
N
º o
f m
ic
ro
n
u
cl
e
a
te
d 
/ 
2 0
00
 p
o
ly
ch
ro
m
a
tic
 e
ry
th
ro
cy
te
Fig. 3. The effect of P1G10 on frequency of micronucleated polychromatic
erythrocytes in mice bone marrow. Erythrocyte counting (2000 polychromatic
erythrocytes) was  done 36 h after a single i.p.  injection of P1G10 (5 or 10 mg/kg),
cyclophosphamide 50 mg/kg or 0.9% NaCl, (n = 5, 3 smears/animal/). The slides were
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Atained with May  Grunwald and analyzed by optical microscopy (100× – immer-
ion). NC, negative control – castor oil, PC, positive control – cyclophosphamide
50  mg/kg). ***p < 0.01 ANOVA, Bonferroni post-test.
ositive control (cyclophosphamide 50 mg/kg) 186.56 ± 35.17
p < 0.05, ANOVA, Bonferroni post-test).
iscussion
Based on a biochemical characterization and pharmacological
ctivities for cysteine proteinases (P1G10 fraction) described in
atex from V. cundinamarcensis we analyze the pharmacokinetics,
istribution and toxicology of this fraction.
Initially, the pharmacokinetics parameters were determined
fter i.v.  administration of radiolabeled P1G10, while the distri-
ution and bioavailability were also determined by p.o.  and s.c.
reatments. These two  last routes were included as previous stud-
es demonstrate the gastric healing and antitumor/antimetastatic
ctivities of this fraction, respectively (Mello et al., 2008; Araujo e
ilva et al., 2015; Dittz et al., 2010, 2015).
The kinetic proﬁles of P1G10 in blood after s.c.  or i.v.  admin-
stration were alike (Fig. 2), the similarity was conﬁrmed upon
etermination of AUC and bioavailability following s.c.  or i.v.  injec-
ion (Table 2). The clearance of P1G10 or metabolites following
.v. administration is explained by a bi-exponential decay function
Fig. 2), appropriately described by a two compartment pharma-
okinetics model (Tang et al., 2004). By applying this function we
etermined the pharmacokinetic parameters, listed in Table 2. The
ow t½ ≈ 18 min  for the distribution (fast phase) and t½ ≈ 190 min
or the elimination (slow phase) were related to rapid excretion of
9mTc-P1G10 or its metabolites. These observations are conﬁrmed
y the high initial uptake in organs related to these processes,
liver, kidneys and bladder) (Table 1). The preferential uptake of
hese organs was evident upon comparison of Kps for kidney or
ladder/urine (Table 1) and those from lipophilic organs (brain,
dipose tissue) that act as efﬁcient barriers for hydrophilic macro-
olecules (Boer and Gaillard, 2007). Values similar to t½ elimination
or P1G10 (≈190 min) were reported for different proteinases.
 t½ = 150 min  elimination interval was established when 99mTc-
treptokinase or 99mTc-urokinase were administered to mice and
etween 160–260 min  in dogs given 131I streptokinase (Coates
t al., 1974; Som et al., 1975). In contrast the elimination t½ in
umans treated with bromelain attained 6.2 h (Castell et al., 1997).
The distribution analysis shows a large uptake of 99mTc-P1G10
n various organs after i.v. and s.c.  relative to p.o.  administration.
s expected, the exception was the high GI presence following p.o.armacognosia 26 (2016) 94–101 99
treatment (Supplementary Fig. 2). These data suggest some type of
interaction between these proteins and the GI compartment. The
classical view asserts that absorption of macromolecules via p.o. is
absent due to enzymatic degradation and/or protein denaturation
inﬂuenced by gastric acidity and the presence of the mucosa bar-
rier (Toon, 1996; Tang et al., 2004; Goldberg and Gomez-Orellana,
2003; Mahmood and Green, 2005). P1G10 may  also undergo pre-
systemic lymphatic clearance, contributing to the reduced uptake
by different organs as described by Wasan (2002) for proteins and
peptide-like drugs. On the other hand, experimental evidence sug-
gests that a small but sizable amount of protein is absorbed through
the gastrointestinal (GI) tract. Mechanisms such as; persorption,
enteropancreatic circulation, receptor speciﬁc absorption, changes
in transepithelial electric resistance and paracellular diffusion are
invoked to explain GI protein transport (Kolac et al., 1996). In our
case the absorption might be facilitated by the mucolytic action
attributed to proteolytic enzymes that split amino acid bonds from
mucus glycoproteins (Bock et al., 1998). Indirect evidence sup-
porting this notion arises from several studies using proteolytic
enzymes as adjuvants that facilitate the passage of non-permeable
drugs (Grabovac et al., 2007). In summary, the relatively small
bioavailability of P1G10 by p.o. (Table 2) compares well with data
for protein absorption documented in mammals (Kolac et al., 1996)
and exceeds the value proposed by Baumann (2006). Overall, the
AUC blood value, obtained after p.o.  route was approximately10-
fold lower than values observed after parenteral administration,
resulting in less than 10% bioavailability (Table 2). Attempts to
identify radiolabeled P1G10 by electrophoresis followed by autora-
diography or HPLC in blood or urine were unsuccessful because of
the large amount of protein contaminants in the sample and the
rapid decay of radioactivity. Therefore, it is possible that the calcu-
lated 8.3% (Table 2) bioavailability represents labeled degradation
products.
An interesting fact arises from analysis of the radioactive
contents in stomach and large intestine after p.o.  administration
(Supplementary Fig. 2). In stomach, a strong rapid increase in
radioactivity occurs lasting about 8 h and in large intestine the
maximal radioactivity was seen after a 4-hour period, decreasing
thereafter. By contrary, i.v. or s.c.  maxima in these organs were
barely detectable throughout the experiment, and the levels
remained stable between 4 and 10 h. The presence of high P1G10
levels in the GI tract explains the oral effectiveness of P1G10 admin-
istration as gastroprotective or gastric healer demonstrated earlier
by Mello et al. (2008) and Araujo e Silva et al. (2015).
We  suggest that distribution of P1G10 in different compart-
ments at short intervals mainly represents the intact protein since
radioactive 99mTc-P1G10 showed no evidence of degradation or
structural changes, following electrophoresis or HPLC analysis after
synthesis (Fig. 1D and E). In addition, assays of stability with the
labeled protein incubated with plasma of mice suggest that only
10% of the radioactivity represents TcO4− plus TcO2 after 24 h incu-
bation at 37 ◦C, thus the bulk radioactivity measured in distribution
experiments corresponds to undegraded protein (Supplementary
Table 1). The low proportion of byproducts was conﬁrmed by
the limited uptake into thyroid, an organ that usually incorpo-
rates radiochemical impurities (Goolden et al., 1971). The literature
describes a number of proteinaceous radiolabeled molecules tar-
geted for pharmacological applications, but few of them belong to
the family of proteinases (Castell et al., 1997; Kolac et al., 1996).
In many of these reports the labeling efﬁciency approximates the
yield observed in our study (Komarek et al., 2005). Thus, consider-
ing the nature of P1G10 and its physicochemical properties, such
as size and hydrophilicity, we correlate these characteristics with
the pharmacokinetics parameters determined with the radiolabe-
led fraction, and justify the rapid clearance, low p.o. bioavailability
and minimum distribution in lipophilic organs.
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The acute toxicity analysis of P1G10 via s.c.  or i.v.  injection
howed that the fraction was not lethal below 20 mg/kg and by p.o.
dministration the animals survived at doses ≤300 mg/kg. There-
ore, the classiﬁcation for this fraction is “harmful” (category 4)
hen ingested (Taussig et al., 1975). Additional symptoms of tox-
city were absent; this examination included: skin or fur, eyes,
ucous membranes, respiratory, circulatory, autonomic, central
ervous system, somatomotor activity and behavioral pattern, as
stablished by OECD 420 (2001).
The signs of phlebitis after i.v. dose and the localized lesion
nsuing s.c.  injection must arise by damage to vessels due to
he proteolytic activity in the sample or by interference of these
nzymes in the haemostatic system, as demonstrated by Bilheiro
t al. (2013). Studies with other proteinases describe bromelain as
aving low toxicity; the LD50 in mice, rats and rabbits was  >10 g/kg,
nd the LD50 above 2 g/kg placing this enzyme below the toxic range
Taussig et al., 1975). Chronic studies in dogs showed that up to
50 mg/kg administered daily lacked toxic effects after a six-month
eriod. In rats, a daily oral dose of 1500 mg/kg had no carcinogenic
r teratogenic activity, did not impair food ingest, histology of heart,
pleen, kidney or hematological parameters (Moss et al., 1963).
n humans oral administration of bromelain (3000 FIP unit/day;
600 mg/day) during ten days did not alter the blood coagulation
arameters. In the case of papain, the enzyme mix  from Carica
apaya, has an oral LD50 of 4.000 mg/kg, and classiﬁes in category 5
USP 34, 2011). Thus, P1G10 has higher toxic potential compared to
romelain and papain, probably due to its high proteolytic activity,
hich ranks 5 to 7-fold higher than papain from C. papaya (Baeza
t al., 1990; Teixeira et al., 2008).
The mutagenic reversion frequency of P1G10 measured by Ames
eversion was similar to the background on each strain and sig-
iﬁcantly lower than the positive control. Moreover, P1G10 at
he highest concentration (10 mg/plate) exhibited a MR  tendency
elow the negative control, suggesting an antimutagenic activity
TA97 + S9, MR  = 0.2, Table 4). Additional Ames experiments com-
ining a promutagenic substances plus P1G10 must be conducted
o conﬁrm or rule out this possibility.
Similarly, the genotoxic potential of P1G10 assessed by the
icronuclei assay at 5 and 10 mg/kg, showed no alteration in fre-
uency of micronucleated polychromatic erythrocytes relative to
he negative control and signiﬁcantly different from the positive
ontrol cyclophosphamide at 50 mg/kg (Fig. 3, p < 0.01 ANOVA, Bon-
erroni post-test. Based on these results, it is concluded that fraction
1G10 lacks mutagenic or genotoxic activities (Pariza and Johnson,
001).
In conclusion, the protein fraction composed by isoforms
f proteolytic enzymes from V. cundinamarcensis shows high
ptake in metabolic and excretion compartments and lower
ioavailability in lipid rich compartments compatible with the
ydrophilic nature of these macromolecules. The fraction does
ot represent a mutagenic or genotoxic hazard at doses exhibit-
ng therapeutic effect. Based on the toxicological studies using
wiss mice the substance ranks as class IV compound, labeled as
armful.
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